Bioinformatics and Biostatistics Role:    Faculty Title:    Assistant Professor Office No:    132 Address:    485 E. Gray St Phone:    502 852 3988 Fax:    502 852 3294 Email:  maiying.kong@louisville.edu

Background
B.S.,    Computational Mathematics, Xian Jiaotong University, Shaanxi, China.
M.S.,   Computational Mathematics, Xian Jiaotong University, Shaanxi, China.
Ph.D., Statistics, 2004, Indiana University, Bloomington, Indiana. (Advisor: Rabi Bhattacharya)
Post-doc in Biostatistics, 2004-2006, University of Texas, M. D. Anderson Cancer Center (Mentor: J. Jack Lee)
Assistant Professor, 2006-current, Department of Bioinformatics and Biostatistics, SPHIS, University of Louisville

Research Interests
My primary research interests are developing biostatistics methods and applying them to basic/clinical/translational research. I have developed statistical methods on dose-response study, combination drug study, preclinical experimental designs, and longitudinal studies. Currently, I am working on longitudinal study and high-dimensional data analyses.

Students Mentored
Ming Wang, MS in Biostatistics, 2008 (joint with Dr. Somnath Datta)
Lin Sun, MS in Biostatistics, 2010
Hyejeong Jang, MS in Biostatistics (expected graduation in April 2011)

Teaching Activities
I have taught one master level course and three doctoral level courses.
PHST 680:   Biostatistical Method I
PHST 781:   Advanced Linear Model
PHST 782:   Generalized Linear Model
PHST 704:   Mixed Effect Models and Longitudinal Data Analyses

Honors and Awards
Trainee Excellence Award Winner, M.D. Anderson Alumni and Faculty Association, March 2006
Starr Fellowship, International Program, Indiana University, 2003-2004
William B. Wilcox Mathematics Award, Indiana University, May 2002

Active Grants
“Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR)
PI: R. Bolli
NIH/ NHLBI  U24 HL094373
Role: Director of the Biostatistics Core
Term: 8/1/2010-7/31/2015
 
“Center of Excellence in Diabetes and Obesity Research”
PI: A. Bhatnagar
NIH/ NCRR 1 P20 RR024489
Role: Biostatistician
Term: 10/01/2008 – 09/30/2013   

“Effects of diesel emissions on vascular Inflammation and thrombosis”
PI: D. Conklin
HEI ACES 
Role: Co-Investigator
Term: 2/1/2010-1/30/2012 

Completed Grants
“Development of Statistical Analyses for Longitudinal Study” 
PI: M. Kong
University of Louisville: Intramural Research Incentive Grants 
Term: 7/1/2008-6/30/2009

“Longitudinal prospective study of PSP”
PI: I. Litvan
CurePSP
Role: Biostatistician
Term: 7/1/2007-6/30/2009

Publications

Journal Articles

1. M. Kong, J. Yan (2011). Modeling and testing treated tumor growth using cubic smoothing splines. Biometrical Journal.  (In press)

2. M. Kong, A. Cambon, M. J. Smith (2011). Extended logistic regression model for studies with interrupted events, seasonal trend, and serial correlation. Communications in Statistics – Theory and Methods (in press).

3. G. J. Godfrey, W. Lockwood, M. Kong, S. Bertolone, A. Raj. (2010). Antibody Development in Pediatric Sickle Cell Patients Undergoing Erythrocytapheresis: A 11-year Review. Pediatric Blood & Cancer 55(6), 1134-1137.

4. J. Fujimoto, M. Kong, J. J. Lee, W. K. Hong, and R. Lotan (2010). Validation of a novel statistical model for assessing the synergy of combined-agent in cancer chemoprevention. Cancer Prevention Research 3: 917-928. (co-first author)

5. M. Kong, M. Zhang, V. Gopalakrishnan, and J. Wolff (2010). Dose-time-effect modeling for in vitro experiments. Statistics in Biopharmaceutical Research 2(1): 84-96.

6. M. Wang, M. Kong, S. Datta (2010). Inference for Marginal Linear Models with Clustered Longitudinal Data for Potentially Informative Cluster Sizes. Statistical Methods in Medical Research (SMMR). doi: 10.1177/0962280209347043 .

7. J. J. Lee, H. Y. Lin, D. D. Liu, and M. Kong (2010). Applying Emax model and interaction index for assessing drug interaction in combination studies. Frontier in Bioscience (E2): 582-601.

8. M. Kong, J. J. Lee (2010). Applying Emax model and bivariate thin plate splines to assessing drug interactions. Frontier in Bioscience (E2): 279-292..

9. Y. Kajiwara, S. Panchabhai, D. D. Liu, M. Kong, J. Jack Lee, and V. A. Levin (2009). Melding a New 3-Dimensional  Agarose Colony Assay with the Emax Model to Determine the Effects of Drug Combinations on Cancer Cells. Technology in Cancer Research & Treatment 8(2): 163-172.

10. JJ. Lee, M. Kong (2009). A confidence interval for interaction index for assessing multiple drug interaction. Statistics in Biopharmaceutical Research 1, 4-17.

11. M. Kong, JJ. Lee (2008). A semiparametric model for assessing drug interaction. Biometrics 64: 396-405.
 
12. C. Salvador, B. Li, R. Hansen, D. E. Cramer, M. Kong, J. Yan (2008). Yeast-derived b-Glucan Augments the Therapeutic Efficacy Mediated by Anti-Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models. Clinical Cancer Research 14, 1239-1247.

13. JJ. Lee, M. Kong, GD. Ayers, R. Lotan (2007). Interaction index and different methods for determining drug interaction in combination therapy. Journal of Biopharmaceutical Statistics 17, 461-480. 

14. R. Bhattacharya, M. Kong (2007). Consistency and asymptotic normal property of estimated effective doses in bioassay. Journal of Statistical planning and Inference 137, 643-658.

15. M. Kong, JJ. Lee (2006). A generalized response surface model with varying relative potency for assessing drug interaction.  Biometrics 62 (4), 986–995.

16. M. Kong, R. Eubank (2006). Monotone smoothing with application to dose-response curves. Communication in Statistics—Computation and Simulation 35, 991-1004

17. M. Kong, R. Bhattacharya, C.  James, A. Basu. (2005). A statistical approach to estimate the 3D size distribution of spheres from 2D size distributions. Geological Society of America Bulletin 117, 244-249.

18. C. Xu, M. Kong (1998). A stable solution method for large sparse matrix linear equations (Chinese). Gongcheng Shuxue xuebao 15, no.4, 28-34.

19. C. Xu, X. Ma, and M. Kong (1996). A class of factorized quasi-Newton methods for nonlinear least squares problems. J. Comput. Math. 14, no. 2, 143-158.

Letter to Editor

1. J. Lee, M. Kong (2011). Response to Comment re: Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Research (in press).

2. J. Lee, M. Kong (2011). Rebuttal to the Response of Chou. Cancer Research (in press).